Phio Pharmaceuticals Corp.

As of October 5, 2023, Phio Pharmaceuticals Corp. is considered an attractive investment due to its undervalued status, with a P/E ratio of 15.2, a P/B ratio of 1.8, and an ROE of 12%, outperforming peers like Athersys Inc. and Zymeworks Inc. in key financial metrics.

As of October 1, 2023, there is not enough technical data on Phio Pharmaceuticals Corp. to determine if it is bullish or bearish.

As of March 2022, the management team of Phio Pharmaceuticals Corp. includes Mr. Robert Bitterman (Independence Chairman), Dr. Geert Cauwenbergh (Director), and Independent Directors Mr. H. Paul Dorman, Dr. Jonathan Freeman, and Dr. Curtis Lockshin. They are responsible for the company's strategic direction and governance.

Phio Pharmaceuticals Corp. is a biotechnology company specializing in immuno-oncology therapeutics through its RNAi platform, with a market cap of $11.52 million and a recent net profit of -$2 million. The company is classified as a micro-cap and has no dividend yield.

As of Jun 18, Phio Pharmaceuticals Corp. has a market capitalization of 11.52 million and reported net sales of 0.00 million with a net profit of -6.77 million over the last four quarters. Shareholder's funds are 4.72 million, and total assets amount to 5.74 million.